Aliceblue ANTInstall and trade smarter everywhere
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the KRM Ayurveda Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
Key metrics and details at a glance.
Price Band
₹135
Per ShareLot Size
1000 Shares
Minimum Investment
₹1,35,000
Issue Size
₹77.49 Cr
Face Value
₹10
Per ShareIPO Type
Book Building - SME
Retail Quota
35.1%
QIB Quota
49.83%
NII Quota
15.07%
Important dates for your applying strategy.
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
92.16%
Promoter Holding (Post-Issue)
67.28%
Issue Type
Book Building - SME
ISIN
INE1MTV01019
Our Company, established in 2019, is operating a network of hospitals and clinics across multiple cities in India as well as marked its presence in abroad through telemedicines consulting and sales. Presently, Company runs 6 (Six) Hospitals and 5 (Five) Clinics at different locations in the country. Though KRM Ayurveda started off as a kidney hospital and it continues to provide specialized treatment for kidney disorders, the Company has widened its horizons in the past few years and has now evolved for various health disorders such as kidney disorder, Liver Cirrhosis, Diabetes, Fatty Liver, Arthritis etc. Company has marked its reach globally as well through Tele-Consultancy Services. Further, we focus on specialized segments within the medical and healthcare domain that address specific health issues and challenges, such as addiction, personal care, wellness, and related areas and for that we are engaged into trading of Ayurvedic medicine, oils and supplements.
Revenue, profit after tax and total assets across the last 3 reported financial years.
Amount in ₹ crore
How the company plans to utilize IPO proceeds.
The funds raised through this IPO will be used for:
Initial public offering up to 57,40,000 equity shares of Rs. 10/- each ("Equity Shares") of KRM Ayurveda Limited ("KRM" or the "Company") for cash at a price of Rs. 135 per equity share (the "Issue Price"), including a share premium of Rs. 125 per equity share (the "issue price") aggregating to Rs. 77.49 crores ("the Issue"). Out of the issue 5,74,000 equity shares aggregating to Rs. 7.75 crores will be reserved for subscription by market maker ("Market Maker Reservation Portion"). The issue less the market maker reservation portion i.e. net issue of upto 51,66,000 equity shares of face value of Rs. 10/- each at an issue price of Rs.135 per equity share aggregating to Rs. 69.74 crores is hereinafter referred to as the "Net Issue". The issue and net issue will constitute 27.00% and 24.30% respectively of the post-issue paid-up equity share capital of the company. Price Band: Rs. 135 per equity share of face value Rs. 10/- each. The floor price is 13.5 times of the face value of the equity shares. Bids can be made for a minimum of 2000 equity shares and in multiples of 1000 equity shares thereafter.
*Subject to approvals and market conditions.
Key competitive advantages and factors to consider before investing.
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
The AYUSH sector in India has grown significantly in recent years, becoming an important part of the country's economy and job market. AYUSH includes traditional forms of medicine such as Ayurveda, Yoga, Unani, Siddha, and Homeopathy. This sector encompasses hospitals, clinics, wellness centers, research, herbal products, education, and holistic health practices. This growth is driven by greater awareness, the rising demand for natural therapies, and government support for traditional medicine. In India, the AYUSH healthcare system is divided into public and private sectors. The public sector focuses on making AYUSH treatments accessible through government-run centers across the country. Meanwhile, the private sector offers a wide range of services, including specialized treatments, wellness programs, and herbal products. India's strong tradition of ancient healing practices and the large number of trained practitioners make AYUSH treatments popular. The AYUSH market in India has seen remarkable growth, skyrocketing from US$ 2.85 billion in 2014 to US$ 24 billion in 2024. This represents nearly a tenfold increase over the past eleven years, showcasing an impressive expansion. This rapid growth is driven by a rising demand, as more people become health-conscious and show a greater preference for holistic treatments. for 9 seconds. Over the past eleven years, India's AYUSH market has soared from US$2.85 billion in 2014 to an impressive US$24 billion in 2024 a nearly tenfold jump. This dramatic growth is driven by a rising public focus on health and a growing preference for natural, holistic treatments. Additionally, the cost-effectiveness of these treatments attracts people from both within India and abroad, making it a go-to destination for holistic healthcare. The affordability and effectiveness of AYUSH therapies have led to increased interest, both domestically and internationally, making India a key player in traditional medicine research and practice.
Our Company was originally incorporated as a Private Limited Company under the name of "KRM Ayurveda Private Limited" under the Companies Act, 2013 vide certificate of incorporation dated September 03, 2019, issued by Registrar of Companies, Delhi, bearing CIN U24239DL2019PTC354658. Further, our Company was converted into a Public Limited Company in pursuance of a special resolution passed by the members of our Company at the Extra Ordinary General Meeting held on November 23, 2024 and the name of our Company was changed from "KRM Ayurveda Private Limited" to "KRM Ayurveda Limited" & Registrar of Companies, CPC has issued a new certificate of incorporation consequent upon conversion dated December 24, 2024 bearing CIN U24239DL2019PLC354658.
Amount in ₹ crore
Amount in ₹ crore
Figures in ₹ crore, on a standalone basis, as reported for FY24 to FY26.